No relation between docetaxel administration route and high-grade diarrhea incidence

Area of Science:

• Pharmacology
• Gastroenterology
• Oncology

Background:

• Oral docetaxel with CYP3A4 inhibitors aims to enhance bioavailability.
• Diarrhea is a frequent, dose-limiting toxicity of oral docetaxel.

Purpose of the Study:

• To investigate the incidence, severity, and cause of oral docetaxel-induced diarrhea.
• To correlate diarrhea with docetaxel exposure and explore mechanisms in preclinical models.

Main Methods:

• Combined preclinical (mouse models) and clinical data analysis.
• Compared diarrhea incidence/severity in patients with docetaxel exposure (AUC, Cmax).
• Evaluated intestinal toxicity in mice with altered Cyp3a and P-glycoprotein expression.

Main Results:

• Diarrhea severity significantly correlated with docetaxel AUC and Cmax in patients.
• Oral docetaxel caused grade 3/4 diarrhea with similar incidence to intravenous administration.
• Mouse studies indicated intestinal toxicity occurred at high systemic exposure, not local exposure.

Conclusions:

• Severe diarrhea from oral docetaxel is driven by systemic blood concentration, not the administration route.
• Intestinal toxicity in mice is related to systemic exposure levels.
• Oral docetaxel-induced diarrhea in humans is reversible and comparable to intravenous administration.